Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

Vitamin C and Reduced Interleukin-6 Levels

Research synthesisModerate evidenceMixed effect size6 studies · 4 beneficial · 2 neutral · 0 harmful

Across 6 papers, 4 report beneficial effects of vitamin C on reducing IL-6 levels, with effect sizes ranging from small to moderate; 2 studies show neutral results. The most-studied dose is 1000 mg/day, and studies primarily involve clinical populations (e.g., cardiac surgery, septic shock, sarcopenia). Effects are observed at durations from acute single doses up to 12 weeks, with a median study duration of 28 days.

  • Effective dose range: 1000 mg daily
  • Studied populations: clinical populations (cardiac surgery, septic shock, sarcopenia, hemodialysis patients)

Caveats: Available evidence is overwhelmingly positive — clinical literature is subject to publication bias (null-result studies are less likely to be published or indexed). Many studies have small sample sizes or short durations; the effect is not always sustained beyond acute use. Results are mixed by dose and population, with some studies showing large effects (e.g., sarcopenia) and others showing no significant change (e.g., asymptomatic COVID-19).

Generated Jun 14, 2026
Doses used in studies
  • mg/day: 250–1,000 (median 1,000, IQR 6251,000) 3 studies
  • IU/day: 60,000 (median 60,000, IQR 60,00060,000) 1 study
  • g/day: 1 (median 1, IQR 11) 1 study
Time to effect
Median: 4 weeks · IQR 7 days8 weeks · Range 1 day2.8 months — Reported in 5 of 6 studies
Safety in these studies
6 of 6 papers
Back to top